QUADRUPLET DARATUMUMAB IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE AS FRONT-LINE REGIMEN IMPROVED CLINICAL OUTCOMES IN HIGH-RISK MYELOMA PATIENTS IN CHINA: A MULTI-CENTERED PROSPECTIVE REAL-WORLD STUDY.
EHA Library, Junling Zhuang,
4160174
BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, INCB057643, IMPROVES BONE MARROW FUNCTION AND SHIFTS MEGAKARYOPOIESIS TO ERYTHROPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)
EHA Library, Diana Alvarez Arias,
4160208
ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-VRD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MYELOMA (NDMM) AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS
EHA Library, Elena Zamagni,
4160157
RETROSPECTIVE STUDY TO DESCRIBE THE CLINICAL CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF TALQUETAMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA TREATED OUTSIDE CLINICAL TRIALS IN SPAIN.
EHA Library, Maria Jesus Blanchard Rodriguez,
4160179
FUNCTIONAL GERIATRIC ASSESSMENT TESTS PREDICT TOXICITY RATES IN FUNCTIONAL HIGH RISK MYELOMA PATIENTS TREATED WITH DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN A PROSPECTIVE CLINICAL TRIAL
EHA Library, Yael Cohen,
4160206